MedTrace Logo

Topotecan and Melphalan for Retinoblastoma

NCT04799002 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-03-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Conditions

  • Retinoblastoma
  • Chemotherapy Effect

Interventions

DRUG

Topotecan

Topotecan intraocular injection for chemotherapy in retinoblastoma

DRUG

Melphalan

Melphalan intraocular injection for chemotherapy in retinoblastoma

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Huashen Yang · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-11
Primary Completion
2024-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04799002 on ClinicalTrials.gov